The US regulator has approved a new use for Amgen’s blockbuster bone drug Xgeva, to prevent fractures in patients with newly-diagnosed multiple myeloma with bone metastases. Xgeva (denosumab ...
At the CIIE, Amgen brings six innovative products-focusing on cardiovascular, bone health, oncology, inflammation and rare diseases-each precisely tailored to the unmet needs of Chinese patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback